211 related articles for article (PubMed ID: 38758478)
1. In vitro results with minimal blood toxicity of a combretastatin A4 analogue.
Chagas C; Mansano JV; da Silva EB; Petri G; da Costa Aguiar Alves Reis B; Schumacher ML; Haddad PS; Pereira EC; Britos TN; Barreiro EJ; Lima LM; Ferreira FF; Fonseca FLA
Invest New Drugs; 2024 Jun; 42(3):318-325. PubMed ID: 38758478
[TBL] [Abstract][Full Text] [Related]
2. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.
McGown AT; Fox BW
Cancer Chemother Pharmacol; 1990; 26(1):79-81. PubMed ID: 2322992
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity and toxicity profiles of 2-benzylidene indanone lead molecule.
Singh A; Fatima K; Singh A; Behl A; Mintoo MJ; Hasanain M; Ashraf R; Luqman S; Shanker K; Mondhe DM; Sarkar J; Chanda D; Negi AS
Eur J Pharm Sci; 2015 Aug; 76():57-67. PubMed ID: 25933717
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X
Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736
[TBL] [Abstract][Full Text] [Related]
6. Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.
Jiang H; Li ZP; Tian GX; Pan RY; Xu CM; Zhang B; Wu JL
Int J Nanomedicine; 2019; 14():1789-1804. PubMed ID: 30880980
[TBL] [Abstract][Full Text] [Related]
7. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Combretastatin-A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach: in vitro Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization.
Jadala C; Sathish M; Anchi P; Tokala R; Lakshmi UJ; Reddy VG; Shankaraiah N; Godugu C; Kamal A
ChemMedChem; 2019 Dec; 14(24):2052-2060. PubMed ID: 31674147
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
10. BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.
Greene LM; Carr M; Keeley NO; Lawler M; Meegan MJ; Zisterer DM
Int J Mol Med; 2011 May; 27(5):715-23. PubMed ID: 21369694
[TBL] [Abstract][Full Text] [Related]
11. Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues.
do Amaral DN; Cavalcanti BC; Bezerra DP; Ferreira PM; Castro Rde P; Sabino JR; Machado CM; Chammas R; Pessoa C; Sant'Anna CM; Barreiro EJ; Lima LM
PLoS One; 2014; 9(3):e85380. PubMed ID: 24614859
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously.
Jiang J; Shen N; Song W; Yu H; Sakurai K; Tang Z; Li G
Biomater Sci; 2019 Dec; 7(12):5283-5291. PubMed ID: 31603448
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of combretastatin A4 analogues on steroidal framework and their anti-breast cancer activity.
Parihar S; Kumar A; Chaturvedi AK; Sachan NK; Luqman S; Changkija B; Manohar M; Prakash O; Chanda D; Khan F; Chanotiya CS; Shanker K; Dwivedi A; Konwar R; Negi AS
J Steroid Biochem Mol Biol; 2013 Sep; 137():332-44. PubMed ID: 23459143
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic activities of MT81 and its structural analogue in Ehrlich ascites carcinoma-bearing Swiss Albino mice.
Choudhury SM; Gupta M; Majumder UK
Oxid Med Cell Longev; 2010; 3(1):61-70. PubMed ID: 20716929
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.
Zhang M; Guo R; Wang Y; Cao X; Shen M; Shi X
Int J Nanomedicine; 2011; 6():2337-49. PubMed ID: 22072871
[TBL] [Abstract][Full Text] [Related]
17. [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
Mouseeva EV; Kuznetsova NR; Svirshchevskaia EV; Bovin NV; Sitnikov NC; Shavyrin AS; Beletskaia IP; Combes S; Fedorov AIu; Vodovozova EL
Biomed Khim; 2012; 58(3):326-38. PubMed ID: 22856138
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combretastatin A4 analogous chalcone and its Pt-complex on cancer cells: A comparative study of uptake, cell cycle and damage to cellular compartments.
Zoldakova M; Kornyei Z; Brown A; Biersack B; Madarász E; Schobert R
Biochem Pharmacol; 2010 Nov; 80(10):1487-96. PubMed ID: 20709029
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118.
Salustiano EJ; Dumas ML; Silva-Santos GG; Netto CD; Costa PR; Rumjanek VM
Invest New Drugs; 2016 Oct; 34(5):541-51. PubMed ID: 27189479
[TBL] [Abstract][Full Text] [Related]
20. 1,2,3,4-tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4.
Lee L; Davis R; Vanderham J; Hills P; Mackay H; Brown T; Mooberry SL; Lee M
Eur J Med Chem; 2008 Sep; 43(9):2011-5. PubMed ID: 18226429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
